BUSINESSFINANCIAL TIMES WORLD
Incyte strikes up to $2bn deal for blood disorder biotech
Incyte has agreed to a potential $2 billion deal for a biotech company specializing in blood disorders. Mid-sized drug manufacturers are enhancing their pipelines and increasing competition with major pharmaceutical companies.
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
- UCB to acquire maker of antibody treatments for autoimmune diseases
- Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO
- Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO